GW Pharma

Committed to Making a Difference

/
Volume | Market Cap | Shares | PEG Ratio | EPS

Fundamentals.

Profile:
HQ: Cambridge, UK
Incorporated: 1998
Symbol: GWPA, GWPRF
Exchanges: NASDAQ, OTC, London, Germany

CEO: Mr. Justin D. Gover

Focus: Strong

Size:
Market Cap: $4.0 bil
Enterprise Value: $3.8 bil
Size by market cap within cannabis industry:     3rd of 200+
# of employees: 600

Markets: Strong
Primary: USA with new Epidiolex drug
Secondary: Sativex: Outside the USA

Operations: Neutral

Production and Distribution: Neutral

Integration/Diversification: Neutral
Vertically integrated: No. It will produce only, and rely on industry channels to distribute the drug
Horizontally diversified: GW has several drugs in the pipeline, so they are trying to be diversified

Financials: Neutral (no revenue yet from new Epidiolex drug, and costs are still very high.)
Earnings/Revenue/Cost control:   $460 mil

Management:
Founder and Exec Chairman: Dr. Geoffrey W. Guy
CEO: Mr. Justin D. Gover
CFO:  Scott M. Giacobello
COO:  Christopher John Tovey BSc

Branding: Neutral

Valuation: Hold

Financings: Strong (GW has a lot of cash, and does not appear to need to raise money.)

Recommendation:  Do not buy  (too expensive)

Get the Q1, ’19 Cannin Report ($99)

Includes the latest market & industry update, 12 technical fundamental analyses, latest regulations by state, new medical research and more!

LEARN MORE

Technicals.

READ GW PHARMACEUTICALS NEWS